Wells Fargo’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $168K | Buy |
52,792
+33,578
| +175% | +$136K | ﹤0.01% | 5296 |
|
|
2026
Q1 | $84.7K | Sell |
19,214
-39,123
| -67% | -$211K | ﹤0.01% | 5189 |
|
|
2025
Q4 | $371K | Buy |
58,337
+3,740
| +7% | +$26K | ﹤0.01% | 4693 |
|
|
2025
Q3 | $509K | Buy |
54,597
+25,163
| +85% | +$254K | ﹤0.01% | 4290 |
|
|
2025
Q2 | $424K | Buy |
29,434
+3,276
| +13% | +$32.3K | ﹤0.01% | 4261 |
|
|
2025
Q1 | $180K | Buy |
26,158
+3,021
| +13% | +$19K | ﹤0.01% | 4781 |
|
|
2024
Q4 | $123K | Buy |
23,137
+6,856
| +42% | +$37.5K | ﹤0.01% | 5085 |
|
|
2024
Q3 | $59.4K | Sell |
16,281
-595
| -4% | -$1.87K | ﹤0.01% | 5285 |
|
|
2024
Q2 | $46.1K | Buy |
16,876
+15,269
| +950% | +$51.1K | ﹤0.01% | 5327 |
|
|
2024
Q1 | $5.59K | Buy |
1,607
+7
| +0.4% | +$13 | ﹤0.01% | 5871 |
|
|
2023
Q4 | $2.29K | Buy |
1,600
+21
| +1% | +$29 | ﹤0.01% | 6083 |
|
|
2023
Q3 | $2.31K | Sell |
1,579
-16
| -1% | -$25 | ﹤0.01% | 6073 |
|
|
2023
Q2 | $2.5K | Buy |
1,595
+19
| +1% | +$28 | ﹤0.01% | 6182 |
|
|
2023
Q1 | $2.41K | Buy |
1,576
+5
| +0.3% | +$9 | ﹤0.01% | 6197 |
|
|
2022
Q4 | $2.64K | Buy |
1,571
+39
| +3% | +$62 | ﹤0.01% | 5939 |
|
|
2022
Q3 | $1K | Sell |
1,532
-35
| -2% | -$56 | ﹤0.01% | 6495 |
|
|
2022
Q2 | $3K | Sell |
1,567
-81,549
| -98% | -$159K | ﹤0.01% | 6246 |
|
|
2022
Q1 | $204K | Sell |
83,116
-12,188
| -13% | -$33.3K | ﹤0.01% | 4969 |
|
|
2021
Q4 | $356K | Buy |
95,304
+16,622
| +21% | +$89.7K | ﹤0.01% | 4931 |
|
|
2021
Q3 | $494K | Buy |
78,682
+46,130
| +142% | +$380K | ﹤0.01% | 4669 |
|
|
2021
Q2 | $320K | Sell |
32,552
-108,128
| -77% | -$943K | ﹤0.01% | 4838 |
|
|
2021
Q1 | $1.31M | Buy |
140,680
+33,270
| +31% | +$264K | ﹤0.01% | 4052 |
|
|
2020
Q4 | $516K | Sell |
107,410
-4,459
| -4% | -$21.7K | ﹤0.01% | 4496 |
|
|
2020
Q3 | $449K | Buy |
111,869
+8,269
| +8% | +$39.9K | ﹤0.01% | 4425 |
|
|
2020
Q2 | $476K | Buy |
103,600
+26,838
| +35% | +$120K | ﹤0.01% | 4359 |
|
|
2020
Q1 | $251K | Buy |
76,762
+6,943
| +10% | +$26.7K | ﹤0.01% | 4533 |
|
|
2019
Q4 | $301K | Buy |
69,819
+11,488
| +20% | +$40.8K | ﹤0.01% | 4724 |
|
|
2019
Q3 | $229K | Buy |
58,331
+758
| +1% | +$3.23K | ﹤0.01% | 4878 |
|
|
2019
Q2 | $268K | Sell |
57,573
-4,818
| -8% | -$20.6K | ﹤0.01% | 4803 |
|
|
2019
Q1 | $261K | Buy |
62,391
+7,216
| +13% | +$26K | ﹤0.01% | 4688 |
|
|
2018
Q4 | $190K | Buy |
55,175
+16,267
| +42% | +$56.5K | ﹤0.01% | 4944 |
|
|
2018
Q3 | $167K | Sell |
38,908
-78,628
| -67% | -$338K | ﹤0.01% | 5093 |
|
|
2018
Q2 | $436K | Buy |
117,536
+64,287
| +121% | +$244K | ﹤0.01% | 4558 |
|
|
2018
Q1 | $223K | Buy |
53,249
+1,502
| +3% | +$7.86K | ﹤0.01% | 4928 |
|
|
2017
Q4 | $304K | Buy |
51,747
+40,747
| +370% | +$220K | ﹤0.01% | 4744 |
|
|
2017
Q3 | $47K | Buy |
11,000
+10,000
| +1,000% | +$36.6K | ﹤0.01% | 5491 |
|
|
2017
Q2 | $4K | Sell |
1,000
-26,099
| -96% | -$82.7K | ﹤0.01% | 5971 |
|
|
2017
Q1 | $73K | Hold |
27,099
| – | – | ﹤0.01% | 5321 |
|
|
2016
Q4 | $90K | Hold |
27,099
| – | – | ﹤0.01% | 5202 |
|
|
2016
Q3 | $81K | Buy |
+27,099
| New | +$99.5K | ﹤0.01% | 5041 |
|
Other funds holding NAGE
SW
TCM
Wells Fargo's NAGE Position: Q2 2026 in Review
Wells Fargo increased its Niagen Bioscience (NAGE) stake by 175% in Q2 2026, buying an estimated $136K and bringing the position to 52,792 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #5296.
Wells Fargo first reported a position in NAGE in Q3 2016 and has held it in 40 quarters since. The position peaked at $1.31M in Q1 2021. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Wells Fargo held 52,792 shares of Niagen Bioscience worth $168K as of Q2 2026.
- Wells Fargo bought 33,578 Niagen Bioscience shares in Q2 2026, an estimated $136K.
- Niagen Bioscience made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5296 holding.
- Wells Fargo first reported a position in Niagen Bioscience in Q3 2016 and has held it in 40 quarters since.
- Wells Fargo's Niagen Bioscience position peaked at $1.31M in Q1 2021.
- 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.